Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 691-697 , December 2008

What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?

  • Claudio Anasetti, MD (Chair, Department of Blood and Marrow Transplantation, Moffitt Cancer Center)

      Affiliations

    • Corresponding Author InformationMoffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. Tel.: +813 745 2557; Fax: +813 745 8468.

References 

  1. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood. 2007;109:3658–3666
  2. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–585
  3. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827–1833
  4. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood. 2007;110:4606–4613
  5. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912–2919
  6. Jones RB. HCT outcomes: a new tool?. Blood. 2005;106:2602–2603
  7. Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001
  8. Chang C, Storer BE, Scott BL, et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood. 2007;110:1379–1387
  9. Schwake CJ, Eapen M, Lee SJ, et al. Differences in characteristics of US hematopoietic stem cell transplantation centers by proportion of racial or ethnic minorities. Biology of Blood and Marrow Transplantation. 2005;11:988–998
  10. Baker KS, Loberiza FR, Yu H, et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. Journal of Clinical Oncology. 2005;23:7032–7042
  11. Serna DS, Lee SJ, Zhang MJ, et al. Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada. Journal of Clinical Oncology. 2003;21:3754–3760
  12. Wofford J, Kemp J, Regan D, et al. Ethnically mismatched cord blood transplants in African Americans: the Saint Louis Cord Blood Bank experience. Cytotherapy. 2007;9:660–666
  13. Karabon L, Wysoczanska B, Bogunia-Kubik K, et al. IL-6 and IL-10 promoter gene polymorphisms of patients and donors of allogeneic sibling hematopoietic stem cell transplants associate with the risk of acute graft-versus-host disease. Human Immunology. 2005;66:700–710
  14. Lin MT, Storer B, Martin PJ, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. The New England Journal of Medicine. 2003;349:2201–2210
  15. Randolph SS, Gooley TA, Warren EH, et al. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. Blood. 2004;103:347–352
  16. Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99:1971–1977
  17. Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplant outcome. Blood. 2004;104:1923–1930
  18. Madrigal A, Shaw BE. Immunogenetic factors in donors and patients that affect the outcome of hematopoietic stem cell transplantation. Blood Cells, Molecules & Diseases. 2008;40:40–43
  19. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007;110:4576–4583
  20. Parham P, McQueen KL. Alloreactive killer cells: hindrance and help for haematopoietic transplants. Nature Reviews. Immunology. 2003;3:108–122
  21. Cooley S, Miller JS, Trachtenberg E, et al. Activating KIR (B haplotype) in unrelated donors improves disease-free survival after HLA-matched and mismatched allogeneic transplantation for acute myeloid leukemia: implications for donor selection using KIR genotyping. Blood. 2007;110:21a;[abstract 43]
  22. Kollman C, Howe CW, Anasetti C, et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood. 2001;98:2043–2051

PII: S1521-6926(08)00090-X

doi: 10.1016/j.beha.2008.10.002

Best Practice & Research Clinical Haematology
Volume 21, Issue 4 , Pages 691-697 , December 2008

Article Tools